Publication | Open Access
Eculizumab Use in Neuromyelitis Optica Spectrum Disorders
18
Citations
24
References
2024
Year
This study provides Class IV evidence that eculizumab reduces annualized attack rates and new MRI lesions in AQP4-IgG+ patients with NMOSD.
| Year | Citations | |
|---|---|---|
Page 1
Page 1